Cited by 613Autoimmune and Inflammatory Disorders ResearchCAR-T cell therapy researchMethemoglobinemia and Tumor Lysis Syndrome

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

Open access

Abstract

Key Points: Cytokine release syndrome caused by T cell-directed therapies may be driven by abnormal macrophage activation and hemophagocytic syndrome. Cytokine-directed therapy can be effective against life-threatening cytokine release syndrome.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2013-02-485623

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 19 references

Cited by

Sorted by citations

See all 613

Metadata

Authors
Teachey, D. T., Rheingold, S. R., Maude, S. L., Zugmaier, G., Barrett, D. M., Seif, A. E., Nichols, K. E., Suppa, E. K., Kalos, M., Berg, R. A., Fitzgerald, J. C., Aplenc, R., Gore, L., & Grupp, S. A.
Affiliations
  • Children's Hospital of Philadelphia (US)
  • Amgen (Germany) (DE)
  • University of Pennsylvania (US)
  • University of Colorado Cancer Center (US)
Venue
Blood
Published
2013-06-27
Volume
121
Issue
26
Pages
5154-5157
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2076560655
Cited by
613
References
19
Citations by year
2026: 19 · 2025: 23 · 2024: 41 · 2023: 52 · 2022: 44 · 2021: 54 · 2020: 68 · 2019: 71 · 2018: 41 · 2017: 63 · 2016: 42 · 2015: 43 · 2014: 41 · 2013: 10
FWCI
32.52
Type
journal article
Language
en
Update notices
erratum (2016-09-08)
Open access
Locations
  • Blood (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (R01CA102646, R01CA116660, T32CA009615, P30CA016520)
Topics
  • Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Health Sciences › Medicine › Hematology › Methemoglobinemia and Tumor Lysis Syndrome
Keywords
blinatumomab, cytokine release syndrome, hemophagocytic lymphohistiocytosis, macrophage activation, bispecific T-cell engagers, B-cell precursor acute lymphoblastic leukemia, tocilizumab, IL-6 receptor inhibition
MeSH terms
Child, Down Syndrome, Follow-Up Studies, Humans, Immune System Diseases, Immunotherapy, Macrophage Activation, Male, Prospective Studies, Syndrome, T-Lymphocytes, Cytotoxic, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Cytokines, Treatment Outcome, Antibodies, Bispecific, Receptors, Interleukin-6, Lymphohistiocytosis, Hemophagocytic, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. https://app.cochat.ai/papers/10.1182/blood-2013-02-485623
The paper
Teachey, D. T., Rheingold, S. R., Maude, S. L., Zugmaier, G., Barrett, D. M., Seif, A. E., Nichols, K. E., Suppa, E. K., Kalos, M., Berg, R. A., Fitzgerald, J. C., Aplenc, R., Gore, L., & Grupp, S. A. (2013). Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. https://doi.org/10.1182/blood-2013-02-485623